4-Methyl-5,6,7,8-tetrahydro-[2]naphthol | 3718-79-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 四氢化萘
• 英文名称: 4-Methyl-5,6,7,8-tetrahydro-[2]naphthol
• 英文别名: 4-Methyl-5,6,7,8-tetrahydronaphthalen-2-ol
• CAS: 3718-79-4
• 化学式: C₁₁H₁₄O
• 分子量: 162.232
• InChiKey: WCAJQFXWQDCGEP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  4-Methyl-5,6,7,8-tetrahydro-[2]naphthol 、 氯乙酸 在 sodium hydroxide 作用下， 生成 4-Methyl-5,6,7,8-tetrahydro-2-naphthyl-oxyessigsaeure
  参考文献：
  名称：

  Orzalesi,H. et al., Bulletin de la Societe Chimique de France, 1972, p. 3855 - 3857

  摘要：

  DOI：
• 作为产物：
  描述：

  4-(4-羟基-2-甲基苯基)丁酸 在 硫酸 作用下， 以 甲醇 为溶剂， 生成 4-Methyl-5,6,7,8-tetrahydro-[2]naphthol
  参考文献：
  名称：

  Synthese des 6- und 7-Methyl-spiro[4.5]deca-6,9-dien-8-ons

  摘要：

  DOI：

  10.1007/bf00913783

文献信息

• [EN] METHODS AND COMPOSITIONS FOR INHIBITION OF RAS<br/>[FR] MÉTHODES ET COMPOSITIONS PERMETTANT L'INHIBITION DE LA RAS
  申请人：ARAXES PHARMA LLC

  公开号：WO2016049568A1

  公开（公告）日：2016-03-31

  Inhibitors of Ras protein, methods to modulate the activity of Ras protein, and methods of treatment of disorders mediated by Ras protein are provided. A method for regulating activity of a K-Ras, H-Ras or N-Ras mutant protein with a compound is described. Disorders that can be treated include cancer, such as hematological cancer, pancreatic cancer, MYH associated polyposis, colorectal cancer, or lung cancer.

  提供了Ras蛋白的抑制剂，调节Ras蛋白活性的方法，以及通过Ras蛋白介导的疾病治疗方法。描述了一种使用化合物调节K-Ras、H-Ras或N-Ras突变蛋白活性的方法。可治疗的疾病包括癌症，如血液癌症、胰腺癌、MYH相关性息肉症、结直肠癌或肺癌。
• [EN] HETEROCYCLIC COMPOUNDS AS INHIBITORS OF RAS AND METHODS OF USE THEREOF<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES EN TANT QU'INHIBITEURS DE RAS ET LEURS PROCÉDÉS D'UTILISATION
  申请人：ARAXES PHARMA LLC

  公开号：WO2018068017A1

  公开（公告）日：2018-04-12

  Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): or a pharmaceutically acceptable salt, stereoisomer or prodrug thereof, wherein A, B, R", Q, W, X, Y, Z, n1, n2and '--" are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also disclosed.

  提供了具有抑制G12C突变KRAS蛋白活性的化合物。这些化合物具有以下结构（I）：或其药学上可接受的盐、立体异构体或前药，其中A、B、R"、Q、W、X、Y、Z、n1、n2和'--'的定义如本文所述。还公开了与制备和使用这些化合物相关的方法，包括含有这些化合物的药物组合物以及用于调节G12C突变KRAS蛋白活性以治疗癌症等疾病的方法。
• [EN] BENZOTHIOPHENE AND BENZOTHIAZOLE COMPOUNDS AND METHODS OF USE THEREOF<br/>[FR] COMPOSÉS À BASE DE BENZOTHIOPHÈNE ET DE BENZOTHIAZOLE ET LEURS PROCÉDÉS D'UTILISATION
  申请人：ARAXES PHARMA LLC

  公开号：WO2018140599A1

  公开（公告）日：2018-08-02

  Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I) or a pharmaceutically acceptable salt, stereoisomer or prodrug thereof, wherein B, Z, Ra, Rb, Rc, R1, L, L1 and E are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided.

  提供了作为G12C突变KRAS蛋白抑制剂活性的化合物。这些化合物具有以下结构（I）或其药用可接受的盐、立体异构体或前药，其中B、Z、Ra、Rb、Rc、R1、L、L1和E如本文所定义。还提供了与制备和使用此类化合物相关的方法，包括含有这些化合物的药物组合物以及用于调节G12C突变KRAS蛋白活性以治疗癌症等疾病的方法。
• [EN] 1-(6-(3-HYDROXYNAPHTHALEN-1-YL)QUINAZOLIN-2-YL)AZETIDIN-1-YL)PROP-2-EN-1-ONE DERIVATIVES AND SIMILAR COMPOUNDS AS KRAS G12C INHIBITORS FOR THE TREATMENT OF CANCER<br/>[FR] DÉRIVÉS DE 1-(6-(3-HYDROXYNAPHTALEN-1-YL)QUINAZOLIN-2-YL)AZÉTIDIN-1-YL)PROP-2-EN-1-ONE ET COMPOSÉS SIMILAIRES UTILISÉS EN TANT QU'INHIBITEURS DE KRAS G12C POUR LE TRAITEMENT DU CANCER
  申请人：ARAXES PHARMA LLC

  公开号：WO2018140514A1

  公开（公告）日：2018-08-02

  Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): (Formula (I)) or a pharmaceutically acceptable salt, stereoisomer thereof, wherein G, Y, R, R1, R2a, R2b, R2c, L, L1 and E are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided. Preferred compounds are quinazoline and quinazolinone derivatives and in particular 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds.

  提供具有抑制G12C突变KRAS蛋白活性的化合物。这些化合物具有以下结构（I）：（化学式（I））或其药学上可接受的盐、立体异构体，其中G、Y、R、R1、R2a、R2b、R2c、L、L1和E如本文所定义。还提供了与制备和使用这些化合物相关的方法，包括含有这些化合物的药物组合物以及调节G12C突变KRAS蛋白活性以治疗癌症等疾病的方法。优选的化合物是喹唑啉和喹唑啉酮衍生物，特别是1-(6-(3-羟基萘基)喹唑啉-2-基)氮杂环丁烯-1-基)丙-2-烯-1-酮衍生物和类似化合物。
• [EN] FUSED N-HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF<br/>[FR] COMPOSÉS N-HÉTÉROCYCLIQUES FUSIONNÉS ET LEURS PROCÉDÉS D'UTILISATION
  申请人：ARAXES PHARMA LLC

  公开号：WO2018140598A1

  公开（公告）日：2018-08-02

  Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I) or a pharmaceutically acceptable salt, stereoisomer or prodrug thereof, wherein A, B, E, L1, Ra. Rb, Rc and ○ are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided.

  本发明提供了具有抑制G12C突变KRAS蛋白活性的化合物。该化合物具有以下结构（I）或其药学上可接受的盐、立体异构体或前药，其中A、B、E、L1、Ra、Rb、Rc和○的定义如本文所述。本发明还提供了与制备和使用这种化合物相关的方法，包括包含这种化合物的制药组合物以及用于治疗癌症等疾病的调节G12C突变KRAS蛋白活性的方法。